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Summary
Objective: To investigate the prevalence of and risk fac-
tors for overweight and diabetes mellitus in long-stay psy-
chiatric inpatients. Method: Statistical analysis of data col-
lected from medical, laboratory, and pharmacy files. Re-
sults: 80% of the 256 patients were suffering from schizo-
phrenia or other psychotic disorders. The prevalence of 
diabetes mellitus was 15%. The prevalence of a disturbed 
glucose tolerance was 14%. Severe overweight (BMI > 30) 
was positively associated with the use of clozapine (odds 
ratio (OR) = 2.7; 95% confidence interval (CI): 1.31–5.75), 
but negatively with the diagnosis schizophrenia (OR = 
0.4; 95% CI: 0.22–0.88). Diabetes mellitus was associated 
with severe overweight (OR = 3.5; 95% CI: 1.57–7.69). Cau-
casian patients were at a lower risk for diabetes mellitus 
(OR = 0.2; 95% CI: 0.08–0.54). Conclusions: In residential 
psychiatric patients, diabetes mellitus is especially asso-
ciated with overweight and non-Caucasian origin. In this 
survey, the use of clozapine was associated with over-
weight, but not directly with diabetes mellitus. Diabetes 
mellitus is highly prevalent, which calls for screening for 
diabetes mellitus at regular intervals.
Introduction
The prevalence of diabetes mellitus in psychiatric patients is 
higher than that in the general population [1]. This is espe-
cially true for schizophrenic patients, who are reported to 
have diabetes mellitus 2–4 times more often [2]. As early as in 
the first half of the 20th century, a relationship between psy-
chiatric diseases and diabetes mellitus was suspected [3, 4]. 
Recently, this hypothesis has been supported by specific re-
ports of an increase in glucose intolerance and insulin resist-
ance in young, drug-naive, schizophrenic patients [5, 6]. The 
existence of a direct relationship is also supported by other 
evidence [7]. Psychiatric patients are prone to develop the 
metabolic syndrome [8]. This is partly due to the influence of 
atypical anti-psychotic medication, which is associated with 
the development of overweight, dyslipidemia, and diabetes 
mellitus type 2 [9].
In long-stay psychiatric inpatients, even more than in the 
general population of psychiatric patients, the risk factors for 
diabetes mellitus, such as a sedentary lifestyle, smoking, over-
weight, and the use of atypical anti-psychotic medication, 
may coincide. This makes such a patient population particu-
larly suitable to study and distinguish the influence of these 
factors. As this patient population has as yet not been exten-
sively studied and since the findings may reflect the situation 
in ambulatory chronic psychiatric patients, we decided to 
conduct a data survey of a population of long-stay psychiatric 
inpatients.
Patients and Methods
All residential patients (n = 256) who were staying in the Delta Psychiat-
ric Center, a general psychiatric hospital of 850 beds in the vicinity of 
Rotterdam, The Netherlands, were eligible for our study. The center has 
a catchment area of 650,000 rural and urban inhabitants. Here, an in-
ternist and a specialized diabetes nurse practitioner are available for the 
treatment and coaching of all patients with diabetes mellitus. Body weight 
342 Obes Facts 2011;4:341–345 Mookhoek/de Vries/Hovens/Brouwers/ 
Loonen
and serum glucose, among other measurements, are recorded at regular 
intervals in all patients. In patients without diabetes, serum glucose is re-
corded at least once every year. From the medical, laboratory, and phar-
macy files of the 256 residential patients, data were collected on gender, 
age, ethnicity, psychiatric diagnoses (Diagnostic and Statistical Manual of 
Mental Disorders fourth edition (DSM-IV)), body mass index (BMI, 
weight in kg, divided by the square of the height, in m2), serum glucose 
levels, and use of anti-diabetic and anti-psychotic medication.
When a patient used anti-diabetic medication, or had fasting serum 
glucose levels over 6.9 mmol/l or non-fasting serum glucose levels over 
11.0 mmol/l, he or she was assumed to have diabetes mellitus. When a 
patient used no anti-diabetic medication and had fasting serum glucose 
levels between 6.1 and 6.9 mmol/l or non-fasting serum glucose levels 
 between 7.0 and 11.0 mmol/l, he or she was assumed to have impaired 
glucose tolerance.
Odds ratios (ORs) were calculated by multiple regression analysis. 
The differences between subgroups were examined with Student’s t-test 
and the chi-square test. The study did not use an external control group. 
This way, we avoided a number of important confounders, such as hous-
ing conditions, income and major differences in lifestyle. Because this is a 
retrospective survey of medical files, no informed consent or ethical ap-
proval was needed for this study.
Results
On one of the long-stay wards, 256 patients were accommo-
dated. This population consisted of 79 women (31%) with a 
mean age of 51 years (standard deviation (SD) 10.7) and 177 
men (69%) with a mean age of 47 years (SD 12.6). 175 pa-
tients (68%) suffered from schizophrenia, and 30 patients 
(12%) suffered from a different psychotic disorder. Data on 
BMI was missing for 10 patients, due to the inability to meas-
ure weight and/or height. No recent serum glucose levels were 
available for 13 patients. 91 patients (36%) had severe over-
weight (BMI > 30). 39 patients (15%) had diabetes mellitus, 
and 36 (14%) had disturbed glucose tolerance. 36 of the pa-
tients with diabetes had type 2 diabetes mellitus. 42 patients 
(16%) were of non-Caucasian origin. The patient characteris-
tics are summarized in table 1.
Overweight (BMI > 25) was positively associated with the 
use of clozapine (OR = 2.5; 95% confidence interval (CI): 
1.12–5.45), and negatively with an Asian background (OR = 
0.2; 95% CI: 0.03–0.84). Severe overweight (BMI > 30) was 
also associated with use of clozapine (OR = 2.7; 95% CI: 1.31–
5.75). Patients with schizophrenia had a lower chance of being 
severely overweight (OR = 0.4; 95% CI: 0.22–0.88). In table 2, 
the patients with severe overweight (BMI > 30) are compared 
with patients without severe overweight (BMI ≤ 30).
In table 3, the patients with diabetes mellitus are compared 
with patients without diabetes mellitus. Also in the compari-
son not corrected for overweight, we found no significant dif-
ferences in the use of atypical anti-psychotic agents. This was 
also the case when we compared the patients with a normal 
Table 1. Patient characteristics
Characteristic feature Value
Female/male  79/177
Mean age  48 years (SD 12.2)
Mean length of stay  12 years (SD 10.4)
Main psychiatric diagnosis (DSM-IV axis 1)
Psychotic disorder (schizophrenia 175) 205
Affective disorder  23
Addiction   1
Organic brain disease   8
Other   7
No axis 1 diagnoses  12
BMI ≤ 30 BMI > 30 Odds ratio BMI > 30 (CI 95%)
Diagnosis
Schizophrenia 113 (67%) 56 (33%) 0.4 (0.22–0.88)
Medication
Clozapinea  60 (56%) 48 (44%) 2.7 (1.31–5.75)
Risperidonea  22 (56%) 17 (44%) 2.1 (0.89–4.76)
Quetiapinea   8 (53%)  7 (47%) 2.7 (0.73–9.73)
Olanzapinea  16 (73%)  6 (27%) 1.3 (0.37–4.27)
Origin
Caucasian 127 (62%) 77 (38%) 0.9 (0.40–1.84)
Hindu   4 (80%)  1 (20%) 0.3 (0.03–3.89)
Mediterranean   5 (71%)  2 (29%) 0.8 (0.12–4.69)
Asian   7 (88%)  1 (13%) 0.4 (0.04–3.47)
Black  11 (50%) 11 (50%) 2.1 (0.79–5.36)
Total 154 (63%) 92 (37%)
*The chances of having severe overweight (BMI > 30) were corrected for age, gender, and all 
 variables in this table. Patients with missing data on body weight or body height are not included in 
these figures.
aSome patients used 2 different atypical anti-psychotic agents.
Table 2. Contributing factors to overweight*
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Discussion
The prevalences of diabetes mellitus and disturbed glucose 
tolerance in this population of residential psychiatric patients 
were 15% and 14%, respectively. This is comparable to the 
figures found by Mukherjee et al. [10] in another population 
of patients with schizophrenia in a long-stay setting. The prev-
alence of diabetes mellitus that we found is unmistakably 
higher than the prevalence of nearly 3.5% for the general 
Dutch population [11]. The prevalence of severe overweight 
(BMI > 30) in our population was 36%. This is also substan-
tially higher than in the general adult Dutch population, in 
which severe overweight was estimated to be approximately 
10% for both men and women [11].
A peculiar finding is that patients with schizophrenia were 
less frequently severely overweight than patient with a differ-
ent diagnosis (OR = 0.4). Possibly this can be attributed to the 
severity of their illness and a relatively poor anti-psychotic 
treatment response, which results in a high level of psychomo-
tor agitation.
glucose tolerance with patients with an impaired glucose tol-
erance and patients with diabetes combined. Diabetes melli-
tus was associated with severe overweight (OR = 3.5; 95% CI: 
1.57–7.69). Patients with a BMI < 25 had a lower probability 
of being diagnosed with diabetes mellitus (OR = 0.2; 95% CI: 
0.05–0.54). The same was true for Caucasian patients (OR = 
0.2; 95% CI: 0.08–0.54).
Table 4 shows the differences in the use of atypical anti-
psychotic agents between patients with an impaired glucose 
tolerance and patients diagnosed with diabetes mellitus. Com-
pared to patients with diabetes, patients with an impaired glu-
cose tolerance were significantly (p < 0.01) more often treated 
with clozapine. There was a tendency for patients with dia-
betes to be treated more often with risperidone, but this dif-
ference was not significant. Patients with a psychotic disorder 
were more often treated with an atypical anti-psychotic agent 
than patients with other psychiatric diagnoses (79% versus 
37%; chi-square p < 0.001). There were no significant differ-
ences in the use of atypical anti-psychotic agents between the 
different ethnic groups.
No diabetes Diabetes Odds ratio (CI 95%)
Diagnosis
Schizophrenia 147 (87%) 22 (13%) 0.7 (0.30–1.74)
BMI
> 30  68 (75%) 23 (25%) 3.5 (1.57–7.69)
< 25  60 (29%)  4 (10%) 0.2 (0.05–0.54)
Medication
Clozapinea  96 (89%) 12 (11%) 0.6 (0.23–1.77)
Risperidonea  27 (69%) 12 (31%) 2.1 (0.74–5.75)
Quetiapinea  12 (80%)  3 (20%) 2.0 (0.37–10.7)
Olanzapinea  20 (91%)  2 (9%) 0.2 (0.02–2.20)
Origin
Caucasian 177 (87%) 27 (13%) 0.2 (0.08–0.54)
Hindu   3 (60%)  2 (40%) 5.6 (0.60–53.3)
Mediterranean   6 (86%)  1 (14%) 3.7 (0.23–60.6)
Asian   6 (38%)  2 (63%) 5.4 (0.74–39.8)
Black  15 (68%)  7 (32%) 2.9 (0.90–9.07)
Total 207 (84%) 39 (16%)
*The chances of having diabetes mellitus were corrected for age, gender, and all variables in this 
table. Patients with missing data on body weight or body height are not included in these figures.
aSome patients used 2 different atypical anti-psychotic agents.
Table 3. Contributing factors to diabetes*
Total Impaired glucose  
tolerance
Diabetes p value (chi-square)
Clozapinea 108 22 (20%) 12 (11%) p < 0.01
Risperidonea  39  5 (13%) 12 (31%) ns
Quetiapinea  15  2 (13%)  3 (20%) ns
Olanzapinea  22  4 (18%)  2 (9%) ns
aSome patients used 2 different atypical anti-psychotic agents.
ns = Not significant.
Table 4. The differences in the use of atypical 
anti-psychotic agents between the patients with 
an impaired glucose tolerance, and the patients 
with diabetes mellitus; influence of atypical 
anti-psychotics
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and West Africans. Other authors also found ethnic differ-
ences in the prevalence of diabetes [20, 21]. They explained 
these differences, partially, with differences in socio-economic 
status, level of education, and lifestyle factors. However, these 
factors are far less important in a population of patients ad-
mitted to long-stay wards. Besides a significantly lower rate of 
overweight in patients of Asian background, we found no dif-
ferences in BMI between the ethnic groups in our survey. The 
ethnic differences we found in the prevalence of diabetes can 
probably be attributed to genetic or developmental factors.
Diabetes in psychiatric patients is associated with an in-
creased mortality rate [22, 23]. Furthermore, comorbid dis-
ease is associated with a reduction in the quality of life. This 
underscores the importance of preventing diabetes. Over-
weight is the most promising target in the prevention of type 2 
diabetes mellitus in this group of patients. As in non-psychiat-
ric patients, physical exercise and dietary measures are the 
two most important approaches for treatment and prevention 
[24, 25]. Richardson et al. [26] argued for integrating physical 
activities in psychiatric treatment programs. That this is diffi-
cult was illustrated by Ussher [27], who described an ambiva-
lent attitude in psychiatric patients towards physical exercise. 
In addition, the effect, size and duration of lifestyle interven-
tions are often limited [28]. Therefore, we favor research into 
more effective ways to prevent and treat obesity in psychiatric 
patients. For instance, Wu et al. [29] found that metformin 
treatment by itself was superior to lifestyle interventions for 
anti-psychotic agent-induced weight gain. They found a com-
bination of metformin treatment and lifestyle interventions to 
be most effective.
Conclusions
In a population of residential psychiatric patients, we found 
the prevalence of diabetes mellitus to be 15%. The results do 
not support the existence of a direct association between dia-
betes mellitus and atypical anti-psychotic agents. We did find 
an association between clozapine and overweight. Risk fac-
tors for diabetes mellitus are overweight and non-Caucasian 
origin.
Disclosure Statement
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The relation between overweight and the use of clozapine 
that we found is well known from the literature [12]. The re-
lation between overweight and the other atypical anti-psy-
chotics was less distinct and not significant. The relative small 
number of patients in our survey who were receiving other 
atypical anti-psychotic agents than clozapine limits the con-
clusions regarding the possible effects of other atypical anti-
psychotic agents. Contrary to other reports, we found no 
 relation between olanzapine and overweight [9, 13]. This may 
be explained by the interventions of the treating physician. 
Clozapine is a unique anti-psychotic drug that cannot easily 
be replaced in well-responding schizophrenic patients. Other 
anti-psychotic drugs do not take such a special position and 
can more easily be avoided in patients who experience side 
effects.
Contradictory to other reports, we found no direct rela-
tionship between diabetes mellitus and the use of atypical 
anti-psychotic agents [13–15]. However, in our study, we 
found a strong relationship between severe overweight and 
diabetes mellitus. Possibly, the diabetogenic effect of atypical 
anti-psychotics is mainly mediated by overweight and is not a 
direct effect of these drugs. This is supported by the findings 
of Sowell et al. [16] who observed no effects of atypical anti-
psychotic agents on the glucose metabolism in healthy volun-
teers. Bushe and Leonard [17] concluded that little evidence 
exists for a direct diabetogenic effect of atypical anti-psycho-
tics. Taylor et al. [18] warned of the possible bias caused by a 
more frequent monitoring of glucose metabolism in patients 
treated with the atypical anti-psychotic agents. It could even 
be argued that the relation between atypical anti-psychotics 
and overweight is not a result of metabolic effects of the 
 atypical anti-psychotics themselves, but that it is a result of 
the absence of rigidity and involuntary movements as part of 
extra-pyramidal movement disorders caused by the older 
anti-psychotic agents. Notwithstanding the unhealthy nature 
of this way of exercising, these movement disorders may have 
prevented overweight by increasing muscular energy con-
sumption. This may also explain our finding that patients with 
schizophrenia had a lower chance of being severely over-
weight. Possibly, the patients with schizophrenia received 
older anti-psychotic agents more often than the patients with 
other psychiatric diagnosis.
In our survey, non-Caucasian patients were more prone to 
develop diabetes mellitus than Caucasian patients, who had 
the lowest OR for diabetes mellitus. Cappucio et al. [19] 
found diabetes to occur more frequently among South Asians 
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